Pratt Collard Advisory Partners LLC Has $859,000 Position in Codexis, Inc. (CDXS)

Pratt Collard Advisory Partners LLC boosted its position in shares of Codexis, Inc. (NASDAQ:CDXS) by 4.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 41,857 shares of the biotechnology company’s stock after buying an additional 1,900 shares during the quarter. Pratt Collard Advisory Partners LLC owned approximately 0.08% of Codexis worth $859,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Quantamental Technologies LLC purchased a new position in Codexis during the fourth quarter valued at $26,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Codexis by 152.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,837 shares of the biotechnology company’s stock worth $47,000 after buying an additional 1,711 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Codexis by 12.1% in the fourth quarter. Legal & General Group Plc now owns 9,379 shares of the biotechnology company’s stock worth $157,000 after buying an additional 1,010 shares in the last quarter. United Services Automobile Association purchased a new position in shares of Codexis in the third quarter worth about $195,000. Finally, Campbell & CO Investment Adviser LLC purchased a new position in shares of Codexis in the fourth quarter worth about $217,000. Institutional investors own 85.29% of the company’s stock.

In related news, insider John J. Nicols sold 55,072 shares of Codexis stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $20.83, for a total value of $1,147,149.76. Following the completion of the transaction, the insider now owns 1,087,751 shares in the company, valued at $22,657,853.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Gordon Sangster sold 75,000 shares of Codexis stock in a transaction that occurred on Friday, January 25th. The stock was sold at an average price of $16.94, for a total transaction of $1,270,500.00. Following the completion of the transaction, the chief financial officer now owns 169,453 shares of the company’s stock, valued at approximately $2,870,533.82. The disclosure for this sale can be found here. Insiders sold 236,987 shares of company stock valued at $4,673,191 in the last quarter. 11.40% of the stock is owned by insiders.

Shares of CDXS stock traded up $0.09 during trading on Tuesday, reaching $20.87. The company’s stock had a trading volume of 4,293 shares, compared to its average volume of 270,764. The stock has a market capitalization of $1.12 billion, a P/E ratio of -99.45 and a beta of -0.32. Codexis, Inc. has a 1-year low of $10.90 and a 1-year high of $23.05.

Codexis (NASDAQ:CDXS) last announced its quarterly earnings data on Tuesday, February 26th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.01. Codexis had a negative net margin of 17.95% and a negative return on equity of 24.35%. The firm had revenue of $16.07 million during the quarter, compared to analysts’ expectations of $16.62 million. Equities analysts forecast that Codexis, Inc. will post -0.14 earnings per share for the current fiscal year.

Several equities analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Codexis from a “buy” rating to a “hold” rating in a research note on Friday, January 18th. ValuEngine upgraded shares of Codexis from a “buy” rating to a “strong-buy” rating in a research report on Monday, April 1st. BidaskClub upgraded shares of Codexis from a “hold” rating to a “buy” rating in a research report on Monday, April 1st. Craig Hallum raised their price objective on shares of Codexis from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, February 27th. Finally, HC Wainwright restated a “buy” rating and set a $16.50 price objective on shares of Codexis in a research report on Monday, January 14th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $21.07.

ILLEGAL ACTIVITY WARNING: “Pratt Collard Advisory Partners LLC Has $859,000 Position in Codexis, Inc. (CDXS)” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.com-unik.info/2019/04/16/pratt-collard-advisory-partners-llc-has-859000-position-in-codexis-inc-cdxs.html.

About Codexis

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Read More: What is an SEC Filing?

Want to see what other hedge funds are holding CDXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Codexis, Inc. (NASDAQ:CDXS).

Institutional Ownership by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit